on behalf of the Severe Aplastic Anemia-Working Party of the EBMT In this article, front-line immunosuppressive therapy (IST) for acquired plastic anemia (AA) is illustrated and discussed. Also secondline and salvage options are briefly illustrated. First-line IST should consist of horse anti-thymocyte globulin (ATG) and CsA that has been shown to result in response rates between 60 and 80%. CsA should be given for 12 months until transfusion independence is achieved and then tapered very slowly in the presence of a CR. Patients with a partial response are usually continued on CsA. Tight monitoring of the blood count during CsA tapering is necessary to identify early loss of response. G-CSF 5 mg/kg/day s.c. in the first 30 days has been shown to reduce infections and hospitalization and to identify early responders, as those who achieve neutrophils count ofX0.5 Â 10 9 /L by day þ 30. This schedule is recommended in the first month of therapy. Afterward, G-CSF can be considered in neutropenic febrile episodes. Patients not achieving transfusion independence after a first course of IST may be considered for second-line IST, or for an allogeneic hematopoietic SCT depending on patient age, ongoing infection, neutrophil count and transfusion requirements. Third-line IST is rarely given, but some options are discussed.
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ANTI-THYMOCYTE GLOBULIN
In Europe until 2007, horse (h)ATG (Lymphoglobuline, Merieux, Lyon, France) was used as upfront treatment; rabbit (r)ATG (Thymoglobuline, Merieux) was adopted as second-line therapy in patient who failed hATG, and provided a response rate between 30 and 77%. 1, 3 In 2007, Lymphoglobuline was withdrawn from the market and European Centers where obliged to use Thymoglobuline as frontline IST. In the USA, another preparation of hATG (ATGAM, Pfizer, New York, NY, USA) has been available and used with similar success rates to Lymphoglobuline.
Unfortunately, results with Thymoglobuline used as front-line IST in AA have been discouraging. A recent prospective randomized study from the National Institutes of Health (NIH), USA, compared hATG (ATGAM) with rATG (Thymoglobuline). 4 This study showed a clear superiority of ATGAM over Thymoglobuline with a response rate at 6 months of 68% in the horse arm vs 37% in the rabbit arm (Po0.001) Three-year probability of survival was 96% in the horse and 66% in the rabbit group (P ¼ 0.04) with data censored at time of SCT and of 94% (horse) vs 70% (rabbit) (P ¼ 0.008) when SCT events were not censored. Of further concern, there were more early deaths (that is, within the first 6 months) among the rabbit-treated patients than in the horse group (9 vs 2).
Another prospective study, with matched historical controls, was run by the Severe Aplastic Anemia Working Party (SAAWP) of the European Group for Blood and Marrow Transplantation (EBMT). 5 This 1/3 case-control study, compared the outcome of AA patients treated upfront with rATG (Thymoglobuline) with that of matched historical controls treated with hATG (Lymphoglobuline). Best response was 60% for rabbit and 67% for hATG. Overall survival at 2 year for rATG, was 68% and 86% for hATG (P ¼ 0.009). Transplant-free survival, an indicator of IST successes preventing the need for subsequent SCT, was significantly greater in the horse arm (76%) compared with the rabbit (52%) (P ¼ 0.002). In addition, fatal infections occurred in about 1/3 of patients given Thymoglobuline, not necessarily early after treatment, when survival is similar to hATG, but rather beyond day þ 100 when survival clearly worsens in rATG-treated patients.
Regarding the reasons for the superior response achieved by horse over rATG, it has been shown that, although both preparations induce a similar CD8 þ cytotoxic T cells depletion, rATG causes a more profound CD4 þ cell depletion. This, in spite of the higher frequency of regulatory T cells seen after rabbit compared with after horse, probably deprives hematopoietic cells the positive effect of CD4 þ cells. 4 Other previous studies showed superior results with horse as compared with rATG. One is a retrospective comparison indicating a significantly greater survival (75% vs about 55%; P ¼ 0.03) and a better hematological response in hATG-treated patients compared with the rATG group. 6 Two further retrospective analyses 7, 8 showed a clear superiority of horse ATG (Lymphoglobuline) over rabbit ATG (Thymoglobuline) both in terms of survival and of response rate. Three studies have shown comparable outcomes between horse and rabbit ATG. In a retrospective Spanish study, 9 the probability of survival was around 70% with both agents and hematological response was 57.8% for rATG and 58.5% (P ¼ NS) for hATG (Lymphoglobuline). In another study, 10 the response rate after 12 months of the 20 patients treated with rATG was 50% whereas in the 67 horse-treated historical controls was 58% (P ¼ NS). A more recent analysis on 30 children showed an equivalent response (55.6% at 12 months) in rabbit vs horsetreated patients.
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Taken together, the above data clearly indicate that hATG provides superior results over rATG in the first-line IST of AA. There are no studies showing superiority of rabbit ATG over horse ATG, and of those showing equivalence of results, none is of a level of evidence 1, that is, prospective randomized trial.
For all these reasons, the SAAWP EBMT recommends that hATG be the preferred ATG to use in front-line IS therapy of patients with AA.
Difficulties in ATGAM supply are faced in many European counties. However, after the actions taken by EBMT SAAWP and by single nations Hematology Association, it seems possible to provide this treatment to an acceptable proportion of patients at least in some countries.
CSA
Oral CsA is another important component of the IS treatment of AA. Usually CsA is recommended for long times and CsA dependence (need to continue the drug to maintain response) has been observed 15-25% of cases. 12 Therefore, the duration and the tapering off of this drug are important issues that were addressed by two studies. The first, conducted on a pediatric population, has shown that CsA at 4-6 mg/kg/day given for 12 months, in combination with ATG, provided a response rate of 71%. Slow tapering of CsA (0.3-0.7 mg/kg/month) resulted in a significantly lower incidence of relapse (7.6%) vs rapid (4 0.8 mg/ kg/month) tapering (60%, P ¼ 0.001) thus suggesting that CsA should have been reduced in no o12 month after stable remission has been achieved. 12 A more recent retrospective and prospective analysis on an adult-based patient population conducted at the NIH provided different results. 13 Indeed relapse rate in patients stopping CsA after 6 months (32%) was not significantly higher (29%, P ¼ 0.42) than that of subjects who, after the first 6 months at full dose, tapered the drug off by 25% of the dose every 3 months over the subsequent 18 months.
The different results of the two studies can be explained by the diversity of the patient population and by the differences in speed of dose reduction. Moreover, in the pediatric study CsA was in general well tolerated whereas in the NIH study, in spite of the need to limit the occurrence of troubling symptoms, CsA toxicity was not analyzed. It can still be possible that the rapid CsA reduction is probably more an adult rather than childhood need and that pediatric patients might experience negative side effects less frequently.
Overall, it still seems reasonable to propose CsA treatment at full dose for 12 months under continued serum level and clinical monitoring and if a CR is achieved then to slowly reduce the dose over another 12 months by 5-10% of the dose per month. Obviously, CsA dose need to be reduced if significant negative side effects occur. In this case, a subsequent slow increase to the maximum tolerated dose can be tried.
G-CSF
Infections during combined IS, are the first cause of death (30%) 2 and adversely affect survival. Most infections tend to occur during the first month from diagnosis and are associated to disease-related neutropenia. Since the early 1990s, G-CSF has been added to ATG and CsA with the aim to reduce infectionrelated mortality.
The increased risk of late clonal diseases after IST regimens containing G-CSF is a concern but data are controversial in this respect. One retrospective study indicates a significantly higher hazard (1.9) of myelodysplastic syndrome/AML associated with use of G-CSF and a significantly worse outcome of relapse in G-CSF-treated patients.
14 However, all prospective randomized trials to date [15] [16] [17] did not show any difference in the risk of clonal disease. One study 15 showed that G-CSF in combination with ATG and CsA reduced the risk of relapse after IS. The most recent and largest prospective randomized study 17 from the SAAWP of the EBMT showed that G-CSF does not affect OS, EFS, response, mortality, risk of clonal disease and relapse, but increased the neutrophil count, reduced infections and days of hospitalization in the first 3 months of treatment. In addition, G-CSF was useful to identify responders: indeed patients achieving neutrophilsX0.5 Â 10 9 /L by day þ 30 on G-CSF had significantly higher chances to respond.
Based on this trial, G-CSF can be used continuously during the first 30 days. After that time the use of G-CSG 'on demand' during infectious episodes in neutropenic patients can be accepted. This strategy might contribute to minimize infectious risks and, given the short-term use, the potential risk of late clonal disease.
OTHER TESTED FRONT-LINE OPTIONS
Over the last years the hypothesis that an increased IST might have been able to produce better responses has been tested. Unfortunately, the addition to ATG/CsA of newer immunosuppressive agents like mofetil micofenolate 18 and sirolimus 19 neither improved response nor decreased the risk of relapse and of clonal disease. In children, tacrolimus in alternative to CsA gave a comparable response rate (88% vs 85%) with a more favorable toxicity profile. 20 Alentuzumab was also prospectively tested as upfront IS option vs horse and rATG in a triple randomized study but response rate was so low (19%) that this arm was closed. 21 In non-severe AA, Daclizumab, a humanized MoAb to the IL-2 receptor, provided a response in 19/45 patients (42%) at 3 months with another two responding at 6 months after a further course of therapy. 22 
SECOND-LINE IS
Before 2007, rATG given as second-line IST after failure to respond to hATG, resulted in 30-77% response rate. 1, 3 Therefore, if hATG (ATGAM) is not available, it would be reasonable to consider treatment with rATG even if response rates are lower, 4,5 rather than no treatment at all. Most studies have adopted the dose of 3.75 mg/kg/day for 5 days that was associated with a high risk of infections and lethal toxic effects. 4, 5 Although experience is limited, a lower dose of rabbit ATG (for example, 2.5 mg/kg/day for 5 days) should be considered with the aim of reducing infectious risks. Alternative second-line IS options include CsA alone. Early unrelated donor hematopoietic SCT using fludarabine--based conditioning regimens may also be an option in view of improved outcomes particularly in younger patients.
SALVAGE TREATMENT
Alemtuzumab has been used in advanced patients who in 450% of cases achieved partial or complete, but in general not durable, response. Viral infections were not especially high but regular monitoring of EBV and CMV viral DNA is recommended. 23 Another study 21 showed that Alentuzumab in refractory patients gave similar response rate (37%) as rATG (33%, P ¼ 0.78) although a nonsignificantly better 3-year survival (83% vs 60%; P ¼ 0.16).
In patients who relapsed (that is, achieved a response that was subsequently lost) alemtuzumab, given in a single-arm study, provided a response rate and a 3-year survival rate of 56% and 86%, respectively.
Other IST options include cyclophosphamide 50 mg/kg/day i.v. for 5 days without hematopoietic SCT rescue resulting in 62% and 48% OS and EFS, respectively, in patients non-responsive or refractory to two or three courses of IST. 24 The infection risk was very high (49%) and often lethal, associated with prolonged pancytopenia after treatment, so there is less enthusiasm for this approach in Europe.
Recently, refractory patients were treated with TPO receptor agonist Eltrombopag. Response rate was 41%, in some cases with normalization of tri-lineage hematopoiesis and cellularity. Side effects, including fibrosis were very limited. 25 This data suggest that some patients' refractory to IS may benefit of treatments expanding the hematopoietic stem cell compartment thus pointing to an intrinsic deficiency of this pool as a potential pathogenic mechanism.
FUTURE PERSPECTIVES
Recent pathogenic studies seem to suggest that several mechanisms may responsible for the disease. Although the immunemediated attack still remains the major one, it looks plausible that other mechanisms like telomerase 25 and/or intrinsic hematopoietic stem cell compartment deficiency 26 may either have an autonomous role or cooperate with the immunomediated effect in some patients.
Therefore, efforts should be directed to detect in each single patient the prevalent pathogenic mechanism. This brings about the need for a wide diagnostic work-up including stem cell function, telomere/telomerase evaluation and exclusion of other genetic marrow failure diseases mimicking acquired AA. This is the case of incompletely expressed forms of dyskeratosis congenita (usually due to TERC and TERT mutations), of Fanconi anemia and of congenital amegakaryocitic thrombocytopenia that, starting from isolated thrombocytopenia, may evolve in early ages to full blown AA virtually indistinguishable from idiopathic acquired AA. This may help to assign patients to treatments tailored to the main pathogenic defect. Similarly, multicentre prospective randomized trials comparing different options (for example, IST vs androgens vs anti-citokine vs eltrombopag), in addition to define the potentiality of each of these treatments, may further contribute to the identification of the fundamental pathogenic mechanism.
OUTLINE OF FIRST-LINE IST ACCORDING TO EBMT GUIDELINES
In summary the recommended guidance of the SAAWP of the EBMT for first-line IST, includes:
1. Horse ATG (Atgam), 40 mg/kg/day i.v. in a 12-to 18-h infusion, for 4 days (days 1-4). 2. CsA 5 mg/kg/day orally from day þ 5 to day þ 365. Trough whole blood CsA levels should be maintained between 150 and 250 ng/ml watching carefully for toxicity (for example, renal insufficiency, hypertension, electrolyte imbalance, neurological complications, and so on). After the first 12 months, if CR has been achieved, CsA can be tailored by 5-10% dose per month up to month þ 24. During tailoring, attention should be posed to the drop of the count. In this case, dose should be re-increased until the count recovers. If negative side effects occur, the dose needs to be reduced. A subsequent slow increase to the maximum tolerated levels can be tried. If CR is not achieved, CsA needs to be maintained for longer. Addition of anabolic steroids (androgens) may be considered. 3. Methylprednisolone (or prednisone) 1-2 mg/kg/day from day þ 1 to day þ 5 as a 30-min i.v. bolus before horse ATG. Oral methylprednisolone (or prednisone) 1 mg/kg/day from day þ 6 to day þ 14 then, tapering off over the next 14 days. Steroids are only aimed to prevent serum sickness. If symptoms of serum sickness occur, tapering should be postponed. 4. G-CSF (lenograstim or filgrastim) 5 mg/kg/day continuously during the first 30 days. After that time point, G-CSF may be considered during febrile or infectious episodes when ANCo0.5 Â 10 9 /L. G-CSF needs to be stopped when infection is cleared or ANC41.0 Â 10 9 /L.
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